Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $4.61B | -5.5% | $117.5M | $0.43 | -17.3% | 25.6% | 8.1% |
| Q4 2025 Dec 2025 | $5.07B | — | $327.1M | $1.14 | +395.7% | 27.4% | 10.8% |
| Q3 2025 Sep 2025 | $4.88B | — | $274.8M | — | — | 25.4% | 10.3% |
| Q2 2025 Jun 2025 | $4.79B | — | $225.3M | $0.77 | — | 25.3% | 8.2% |
| Q1 2025 Mar 2025 | $4.88B | — | $151.2M | $0.52 | — | 24.3% | 7.8% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Fresenius Medical Care quarter with profit surge, strong cost-cutting program – but the cautious 2026 outlook significantly weighs on the stock.